Harmony Biosciences Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Harmony Biosciences Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cash flows from operating activities | |||||||||||||||||||
| net income | 39,776,000 | 45,560,000 | 49,475,000 | 46,093,000 | 11,591,000 | 38,334,000 | 26,607,000 | 38,461,000 | 34,300,000 | 29,485,000 | 48,509,000 | 87,943,000 | 23,531,000 | 21,485,000 | 22,714,000 | -9,620,000 | 14,117,000 | 7,386,000 | -208,000 |
| adjustments to reconcile net income to net cash from operating activities: | |||||||||||||||||||
| depreciation | 6,000 | 7,000 | 6,000 | 7,000 | 91,000 | 163,000 | 164,000 | 144,000 | 103,000 | 103,000 | 107,000 | 101,000 | 94,000 | 117,000 | 117,000 | 99,000 | 100,000 | 100,000 | 100,000 |
| intangible amortization | 5,961,000 | 5,961,000 | 5,962,000 | 5,961,000 | 5,961,000 | 5,961,000 | 5,961,000 | 5,962,000 | 5,961,000 | 5,961,000 | 5,961,000 | 5,962,000 | 5,961,000 | 5,082,000 | 4,643,000 | 4,573,000 | 4,629,000 | 4,579,000 | 4,283,000 |
| acquired in-process research & development (ipr&d) expense | 1,000,000 | 0 | |||||||||||||||||
| stock-based and employee stock purchase compensation expense | 11,455,000 | 12,499,000 | 10,072,000 | 11,048,000 | 11,088,000 | 10,394,000 | 8,863,000 | 7,991,000 | 7,648,000 | 7,203,000 | 7,260,000 | 7,007,000 | 7,278,000 | 4,628,000 | 4,198,000 | 4,253,000 | |||
| stock appreciation rights market adjustment | -61,000 | -49,000 | -216,000 | 400,000 | -125,000 | 40,000 | 32,000 | -34,000 | 145,000 | -642,000 | 411,000 | -40,000 | 93,000 | 268,000 | 185,000 | 391,000 | -80,000 | -50,000 | 101,000 |
| debt issuance costs amortization | 163,000 | 166,000 | 169,000 | 175,000 | 176,000 | 180,000 | 185,000 | 1,249,000 | 424,000 | 416,000 | 422,000 | 418,000 | 411,000 | 412,000 | 418,000 | 459,000 | 697,000 | 664,000 | 1,392,000 |
| deferred taxes | -6,485,000 | -4,311,000 | -6,712,000 | -4,830,000 | -14,279,000 | -3,477,000 | 1,123,000 | -6,907,000 | -4,193,000 | -3,442,000 | -4,264,000 | ||||||||
| amortization of premiums and accretion of discounts on investment securities | -453,000 | -451,000 | -491,000 | -550,000 | -626,000 | -594,000 | -684,000 | -719,000 | -676,000 | -636,000 | |||||||||
| other non-cash expenses | 465,000 | 467,000 | 481,000 | 493,000 | 659,000 | 467,000 | 510,000 | 459,000 | 430,000 | 369,000 | 484,000 | 272,000 | |||||||
| change in operating assets and liabilities: | |||||||||||||||||||
| trade receivables | 12,988,000 | -22,936,000 | -1,531,000 | 1,655,000 | -3,438,000 | -5,579,000 | -6,876,000 | -3,452,000 | -11,237,000 | 2,165,000 | 325,000 | -5,243,000 | -11,689,000 | -3,290,000 | -1,637,000 | -2,011,000 | -7,580,000 | -1,439,000 | -5,851,000 |
| inventory | 284,000 | 814,000 | -283,000 | -1,272,000 | 214,000 | -494,000 | -276,000 | -233,000 | -764,000 | 207,000 | -397,000 | 308,000 | 389,000 | -165,000 | 373,000 | 146,000 | -546,000 | -582,000 | -1,512,000 |
| prepaid expenses and other assets | -3,587,000 | -1,999,000 | 1,843,000 | -847,000 | -565,000 | -3,439,000 | 1,833,000 | -3,986,000 | 1,635,000 | 592,000 | -3,069,000 | -772,000 | -1,472,000 | -2,235,000 | 2,124,000 | -3,093,000 | -326,000 | -296,000 | 1,606,000 |
| trade payables | 10,842,000 | 3,715,000 | 3,212,000 | -12,151,000 | 6,141,000 | -2,586,000 | 6,196,000 | -24,000 | 149,000 | 2,628,000 | -6,263,000 | 3,388,000 | -243,000 | 5,903,000 | -3,178,000 | 2,173,000 | -2,385,000 | 1,835,000 | -6,791,000 |
| other liabilities | -7,027,000 | -5,456,000 | 12,575,000 | 24,319,000 | -16,866,000 | -8,229,000 | |||||||||||||
| net cash from operating activities | 79,327,000 | 33,987,000 | 75,562,000 | 70,501,000 | 42,617,000 | 31,141,000 | 76,665,000 | 63,100,000 | 37,063,000 | 42,559,000 | 26,678,000 | 55,205,000 | 33,731,000 | 28,852,000 | 37,533,000 | 30,424,000 | 10,047,000 | ||
| capex | -4,000 | -128,000 | -513,000 | -3,000 | -632,000 | -5,000 | -107,000 | 0 | 0 | 0 | 0 | -86,000 | -41,000 | -45,000 | 0 | -93,000 | 0 | ||
| free cash flows | 79,323,000 | 33,859,000 | 75,049,000 | 70,498,000 | 41,985,000 | 31,136,000 | 76,558,000 | 63,100,000 | 37,063,000 | 42,559,000 | 26,678,000 | 55,119,000 | 33,690,000 | 28,807,000 | 37,533,000 | 30,331,000 | 10,047,000 | ||
| cash flows from investing activities: | |||||||||||||||||||
| purchase of investment securities | -23,900,000 | -19,132,000 | -35,685,000 | -23,287,000 | -21,211,000 | -25,106,000 | -21,613,000 | -33,009,000 | -25,071,000 | -47,776,000 | -55,092,000 | -33,231,000 | |||||||
| proceeds from maturities and sales of investment securities | 19,315,000 | 21,622,000 | 30,011,000 | 24,035,000 | 25,556,000 | 18,925,000 | 22,622,000 | 32,196,000 | 17,505,000 | 45,986,000 | 8,197,000 | ||||||||
| purchase of property and equipment | -4,000 | -128,000 | -513,000 | -3,000 | -632,000 | -5,000 | -107,000 | 0 | 0 | -86,000 | -41,000 | -45,000 | 0 | -93,000 | -201,000 | -4,000 | 0 | ||
| acquisition of epygenix therapeutics, inc., net of cash acquired | 0 | 0 | |||||||||||||||||
| payment of upfront fee related to research collaboration, option and license agreement | |||||||||||||||||||
| net cash from investing activities | -19,589,000 | 2,362,000 | -7,187,000 | 745,000 | -54,856,000 | -6,186,000 | -36,065,000 | -813,000 | -7,771,000 | -1,790,000 | -46,895,000 | -32,445,000 | -22,447,000 | -40,045,000 | 0 | -93,000 | -201,000 | -100,004,000 | -2,000,000 |
| cash flows from financing activities: | |||||||||||||||||||
| principal repayment of long-term debt | -3,750,000 | -3,750,000 | -3,750,000 | ||||||||||||||||
| payments of employee withholding taxes related to stock-based awards | -1,033,000 | -1,308,000 | -2,228,000 | 0 | 0 | 0 | |||||||||||||
| proceeds from exercised options | 2,097,000 | 4,706,000 | 3,237,000 | 2,575,000 | 573,000 | 116,000 | 227,000 | 244,000 | 675,000 | 3,909,000 | 3,566,000 | 2,142,000 | 1,250,000 | 1,883,000 | 7,577,000 | 1,134,000 | 648,000 | 12,000 | 16,000 |
| net cash from financing activities | -2,686,000 | -352,000 | -2,741,000 | -1,175,000 | -3,446,000 | -3,634,000 | -53,523,000 | -55,099,000 | -339,000 | 3,409,000 | 2,658,000 | 2,050,000 | 750,000 | 1,383,000 | 7,072,000 | -313,000 | 648,000 | 12,000 | -1,156,000 |
| net increase in cash, cash equivalents, and restricted cash | 57,052,000 | 35,997,000 | 65,634,000 | 70,071,000 | -15,685,000 | 21,321,000 | -12,923,000 | 7,188,000 | 28,953,000 | 44,178,000 | -17,559,000 | 24,810,000 | 44,605,000 | 30,018,000 | 18,517,000 | -87,462,000 | 6,891,000 | ||
| cash, cash equivalents, and restricted cash—beginning of period | 0 | 453,271,000 | 0 | 0 | 0 | 311,930,000 | 0 | 0 | 0 | 244,534,000 | 0 | 0 | 0 | 235,059,000 | 0 | 0 | 0 | 229,381,000 | 0 |
| cash, cash equivalents, and restricted cash—end of period | 57,052,000 | 489,268,000 | 65,634,000 | 70,071,000 | -15,685,000 | 333,251,000 | -12,923,000 | 7,188,000 | 28,953,000 | 288,712,000 | -17,559,000 | 24,810,000 | 12,034,000 | 225,249,000 | 44,605,000 | 30,018,000 | 18,517,000 | 141,919,000 | 6,891,000 |
| supplemental disclosure of cash flow information: | |||||||||||||||||||
| cash paid during the year for interest | 3,463,000 | 4,197,000 | 4,147,000 | 4,226,000 | 4,359,000 | 4,585,000 | 4,398,000 | 4,962,000 | 5,674,000 | 5,017,000 | 5,030,000 | 3,810,000 | 3,695,000 | 3,829,000 | 3,833,000 | 2,905,000 | 6,582,000 | 6,510,000 | 6,654,000 |
| cash paid during the year for taxes | 21,086,000 | 16,456,000 | 11,690,000 | 16,653,000 | |||||||||||||||
| loss on debt extinguishment | 0 | 0 | 0 | ||||||||||||||||
| acquisition of zynerba pharmaceuticals, inc., net of cash acquired | |||||||||||||||||||
| payment of license fee and milestone | |||||||||||||||||||
| proceeds from long-term debt | |||||||||||||||||||
| debt issuance costs | 0 | -5,000 | 0 | ||||||||||||||||
| extinguishment of debt | 0 | 0 | 0 | ||||||||||||||||
| extinguishment of debt exit fees | 0 | 0 | 0 | ||||||||||||||||
| repurchase of common stock | -50,000,000 | 0 | |||||||||||||||||
| payment of license fee | 0 | ||||||||||||||||||
| principal repayment of long term debt | -3,750,000 | -3,750,000 | -3,750,000 | 0 | -500,000 | -500,000 | -500,000 | -500,000 | -500,000 | -500,000 | |||||||||
| accrued expenses and other current liabilities | 30,765,000 | 14,425,000 | 3,139,000 | -1,850,000 | -22,601,000 | 37,764,000 | 8,993,000 | -3,586,000 | 7,802,000 | 6,855,000 | 5,542,000 | -2,936,000 | 10,712,000 | ||||||
| other non-current liabilities | 2,000 | -2,000 | 0 | 1,000 | 0 | -152,000 | -162,000 | 53,000 | -5,000 | -32,000 | 127,000 | ||||||||
| milestone payments | 0 | 0 | 0 | -40,000,000 | 0 | ||||||||||||||
| proceeds from issuance of common stock | 0 | ||||||||||||||||||
| common stock issuance costs | 0 | ||||||||||||||||||
| proceeds from issuance of debt | |||||||||||||||||||
| proceeds from long term debt | 0 | 0 | |||||||||||||||||
| warrant expense | 0 | ||||||||||||||||||
| proceeds from issuance of common stock upon initial public offering | 0 | ||||||||||||||||||
| initial public offering issuance costs | -1,172,000 | ||||||||||||||||||
| tax payments for employees shares withheld | 0 | ||||||||||||||||||
| supplemental disclosures of noncash investing and financing activities: | |||||||||||||||||||
| series a preferred stock accrued return | 0 | ||||||||||||||||||
| series a accretion of issuance costs | 0 | ||||||||||||||||||
| series b preferred stock accrued return | 0 | ||||||||||||||||||
| series b accretion of issuance costs | 0 | ||||||||||||||||||
| series c preferred stock accrued return | 0 | ||||||||||||||||||
| series c accretion of issuance costs | 0 | ||||||||||||||||||
| warrant financing | 0 | ||||||||||||||||||
| warrant liability reclassified to equity | 0 | ||||||||||||||||||
| investment securities interest income | |||||||||||||||||||
| non-cash lease expense | 385,000 | ||||||||||||||||||
| net decrease in cash, cash equivalents, and restricted cash | -9,810,000 | ||||||||||||||||||
| milestones associated with acquired in-process research & development | |||||||||||||||||||
| noncash paid-in-kind interest expense | |||||||||||||||||||
| other non-current assets | 1,265,000 | ||||||||||||||||||
| proceeds from issuance of preferred stock | |||||||||||||||||||
| preferred stock issuance costs | |||||||||||||||||||
| milestone and acquisition of intangible asset | 0 | -100,000,000 | |||||||||||||||||
| cash paid during the year for milestones | 0 | 100,000,000 | |||||||||||||||||
| stock-based compensation expense | 3,301,000 | 2,823,000 | |||||||||||||||||
| net provided by (cash used) in operating activities | 12,530,000 | ||||||||||||||||||
| milestone associated with acquired in-process research & development |
We provide you with 20 years of cash flow statements for Harmony Biosciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Harmony Biosciences stock. Explore the full financial landscape of Harmony Biosciences stock with our expertly curated income statements.
The information provided in this report about Harmony Biosciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.